packagingAstraZeneca.jpg” style=”padding: 10px” width=”320″ />

AstraZeneca has opened its new production and packaging plant in Kaluga, Russia.

Worth around $224m, the facility represents the largest foreign investment made for developing a new pharmaceutical facility in the country.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Commercial production for the plant has been scheduled to start next year.

Expected to be completely operational in 2017, the production and packaging facility will be used by the company for final-stage manufacturing, packaging and quality control of its products.

"This opening builds on our investments in clinical research and scientific collaborations in this important country."

AstraZeneca CEO Pascal Soriot said: "This opening builds on our investments in clinical research and scientific collaborations in this important country and serves to reinforce our long-term commitment to Russia."

The plant will have a capacity to produce nearly 40 million packs and 850 million tablets of around 30 medicines every year for the pharmaceutical and biologics company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The capacity accounts for more than 60% of AstraZeneca’s medicines marketed in Russia for treatment of diseases across its therapy areas.

This plant is expected to support the AstraZeneca’s global expansion plans, which intend to cater to the rising market demands for its portfolio of medicines.

The firm has recently invested in biologics manufacturing operations in Sweden, acquired a new site in Boulder, Colorado, US, and expanded its capabilities at Frederick in Maryland, US.

Image: Capacity of the new facility accounts for more than 60% of AstraZeneca’s medicines marketed in Russia. Photo: courtesy of AstraZeneca.